BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17573893)

  • 1. Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin.
    Briganti A; Shariat SF; Chun FK; Hutterer GC; Roehrborn CG; Gallina A; Rigatti P; Valiquette L; Montorsi F; Karakiewicz PI
    BJU Int; 2007 Sep; 100(3):528-32. PubMed ID: 17573893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer.
    Briganti A; Chun FK; Salonia A; Gallina A; Farina E; Da Pozzo LF; Rigatti P; Montorsi F; Karakiewicz PI
    BJU Int; 2006 Oct; 98(4):788-93. PubMed ID: 16796698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer.
    Briganti A; Capitanio U; Chun FK; Gallina A; Suardi N; Salonia A; Da Pozzo LF; Colombo R; Di Girolamo V; Bertini R; Guazzoni G; Karakiewicz PI; Montorsi F; Rigatti P
    Eur Urol; 2008 Oct; 54(4):794-802. PubMed ID: 18514383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.
    Briganti A; Karakiewicz PI; Chun FK; Suardi N; Gallina A; Abdollah F; Freschi M; Doglioni C; Rigatti P; Montorsi F
    Int J Urol; 2009 Aug; 16(8):676-81. PubMed ID: 19602006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection.
    Briganti A; Karakiewicz PI; Chun FK; Gallina A; Salonia A; Zanni G; Valiquette L; Graefen M; Huland H; Rigatti P; Montorsi F
    Eur Urol; 2007 Jun; 51(6):1573-81. PubMed ID: 17293026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy.
    Briganti A; Chun FK; Salonia A; Gallina A; Zanni G; Scattoni V; Valiquette L; Rigatti P; Montorsi F; Karakiewicz PI
    Urology; 2007 Jan; 69(1):147-51. PubMed ID: 17270638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer.
    Briganti A; Gallina A; Suardi N; Chun FK; Walz J; Heuer R; Salonia A; Haese A; Perrotte P; Valiquette L; Graefen M; Rigatti P; Montorsi F; Huland H; Karakiewicz PI
    BJU Int; 2008 Mar; 101(5):556-60. PubMed ID: 18005204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection.
    Salonia A; Briganti A; Gallina A; Karakiewicz P; Shariat S; Freschi M; Zanni G; Capitanio U; Bosi E; Rigatti P; Montorsi F
    Urology; 2009 Apr; 73(4):850-5. PubMed ID: 19038425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
    Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
    Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy.
    Briganti A; Chun FK; Salonia A; Zanni G; Scattoni V; Valiquette L; Rigatti P; Montorsi F; Karakiewicz PI
    Eur Urol; 2006 Jun; 49(6):1019-26; discussion 1026-7. PubMed ID: 16530933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
    Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
    J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer.
    Gallina A; Karakiewicz PI; Chun FK; Briganti A; Graefen M; Montorsi F; Walz J; Jeldres C; Erbersdobler A; Salonia A; Suardi N; Dehò F; Schlomm T; Scattoni V; Haese A; Heinzer H; Valiquette L; Rigatti P; Huland H
    BJU Int; 2007 Jun; 99(6):1404-8. PubMed ID: 17428250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer.
    Gallina A; Chun FK; Suardi N; Eastham JA; Perrotte P; Graefen M; Hutterer G; Huland H; Klein EA; Reuther A; Montorsi F; Briganti A; Shariat SF; Roehrborn CG; de la Taille A; Salomon L; Karakiewicz PI
    BJU Int; 2008 Jun; 101(12):1513-8. PubMed ID: 18422773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients.
    Chun FK; Briganti A; Antebi E; Graefen M; Currlin E; Steuber T; Schlomm T; Walz J; Haese A; Friedrich MG; Ahyai SA; Eichelberg C; Salomon G; Gallina A; Erbersdobler A; Perrotte P; Heinzer H; Huland H; Karakiewicz PI
    BJU Int; 2006 Dec; 98(6):1204-9. PubMed ID: 17034506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
    Chun FK; Briganti A; Gallina A; Hutterer GC; Shariat SF; Antebie E; Walz J; Roehrborn CG; Salonia A; Rigatti P; Saad F; Huland H; Montorsi F; Graefen M; Karakiewicz PI
    Eur Urol; 2007 Oct; 52(4):1067-74. PubMed ID: 17383807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores.
    Briganti A; Larcher A; Abdollah F; Capitanio U; Gallina A; Suardi N; Bianchi M; Sun M; Freschi M; Salonia A; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):480-7. PubMed ID: 22078338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection.
    Hansen J; Rink M; Bianchi M; Kluth LA; Tian Z; Ahyai SA; Shariat SF; Briganti A; Steuber T; Fisch M; Graefen M; Karakiewicz PI; Chun FK
    Prostate; 2013 Jan; 73(2):211-8. PubMed ID: 22821742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients.
    Weckermann D; Dorn R; Trefz M; Wagner T; Wawroschek F; Harzmann R
    J Urol; 2007 Mar; 177(3):916-20. PubMed ID: 17296375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.